stella
← For Researchers/Sickle Cell Disease

Sickle Cell Disease

June 2026 Research Brief

Read our full Sickle Cell Disease guide →

Active sponsors

Trials

Stem cell transplantPh 1 / Ph 2
Partial stem cell transplant from matched donors for patients with severe sickle cell disease or beta-thalassemia requiring blood transfusions.

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

National Heart, Lung, and Blood Institute (NHLBI)Posted: May 2026NCT07599176
Kelly S Norris, R.N.kelly.norris@nih.gov
Digital healthPh 1 (early)
Virtual reality supportive care intervention called Amani to improve coping and peer support for adults with sickle cell disease.

Feasibilty and Acceptability of Amani

Massachusetts General HospitalPosted: Jun 2026NCT07648043
Richard A Newcomb, MDrichard.newcomb@mgh.harvard.edu
Gene therapy
Gene therapy using lentivirus vector to induce fetal hemoglobin production in patients with sickle cell disease.

Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease

David WilliamsPosted: Jun 2026NCT07640815
Vaccine
Study tracking invasive bacterial infections in French children with sickle cell disease from 2020-2025 to guide prevention strategies.

Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025

Assistance Publique - Hôpitaux de ParisPosted: Jun 2026NCT07639008
Jean Gaschignardj.gaschignard@ghne.fr
Stem cell transplantPh 2
Reduced toxicity stem cell transplant from half-matched donors with post-transplant cyclophosphamide for children with sickle cell disease.

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

St. Jude Children's Research HospitalPosted: Jun 2026NCT07616154
Akshay Sharma, MDreferralinfo@stjude.org
Drug / intervention
Mobile health screening system in Uganda to improve newborn sickle cell disease detection and coordinated care access.

Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening

Makerere UniversityPosted: May 2026NCT07610239
Mwanje Kavuma Mwanjemwanjemobo@gmail.com
Observational
Research examines how genetic variants in the PKLR gene affect sickle cell disease severity and red blood cell function.

Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease

National Heart, Lung, and Blood Institute (NHLBI)Est. completion: Jul 2026NCT03685721
Dianna S Lovinsdianna.lovins@nih.gov
Drug / interventionPh 3
Automated blood exchange transfusions to reduce health crises in high-risk sickle cell patients.

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

University of PittsburghEst. completion: Jul 2026NCT04084080
Diagnostics
Ultrasound imaging feasibility and reliability for diagnosing acute chest syndrome in hospitalized sickle cell patients.

Ultrasound Acute Chest Syndrome Sickle Cell Disease

Indiana UniversityEst. completion: Jun 2026NCT06880679
Thomas Fisher-Heath, DOtcfisher@iu.edu
Cell therapyPh 2
Tocilizumab drug to treat acute chest syndrome complications in sickle cell disease patients.

Tocilizumab for Acute Chest Syndrome

University of ChicagoEst. completion: Jul 2026NCT05640271

Showing trials with activity in the past 30 days. See the full Sickle Cell Disease research landscape →

Recently completed · awaiting results

Drug / interventionPh 2
Losartan medication to reduce heart scarring in sickle cell disease patients aged 6+.

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

Children's Hospital Medical Center, CincinnatiEst. completion: Oct 2025NCT05012631

Condition guide

Sickle Cell Disease — the full picture

Research landscape, trial types, and what eligibility typically looks like — written for patients but useful for everyone.

Read the condition guide →

Monthly digest

Get this brief every month

We’ll email you the Sickle Cell Diseasebrief as soon as it’s published — no login required.

Coming soon